arrow
G

Genoile Oliveira Santana

Universidade Federal de Juiz de Fora
H指数:17
被引数:1,278

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Inflammatory Bowel Disease in Elderly Versus Non-Elderly Adults: A Cross-Sectional Study in Salvador, Brazil

老年人与非老年人炎症性肠病比较:巴西萨尔瓦多横断面研究

2025-12-010
PRE
Fatigue and Associated Clinical Characteristics in Patients With Crohn's Disease in the State of Bahia, Brazil

克罗恩病患者中的疲劳及其相关临床特征——巴西巴伊亚州研究

2025-12-010
PRE
Fatigue and Associated Variables in Patients With Crohn's Disease Undergoing Pharmacological Treatment

克罗恩病患者在接受药物治疗期间疲劳及相关变量研究

2025-12-010
PRE
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING study

溃疡性结肠炎稳定缓解期患者托法替布减量后的疗效结局潜在预测因子:RIVETING研究结局数据的回顾性分析

2025-02-270
OA
Analysis of Fistula Cases in Crohn's Disease Patients from Brazilian National GEDIIB Registry
2024-12-010
OA
Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB
2024-02-211
OAAI
Evaluation of the Quality-of-Care Parameters in Patients With Inflammatory Bowel Disease in Brazilian Hospitals
2023-12-010
OA
Clinical Profile of Patients With Inflammatory Bowel Disease in Brazil: Analysis of the National Registry (GEDIIB)
2023-12-010
OA
Anorectal Function and Clinical Characteristics Associated with Faecal Incontinence in Patients with Crohn's Disease
2023-03-232
PRE
Variables associated with progression of moderate-to-severe Crohn's disease

与中重度克罗恩病进展相关的变量

2022-11-154
OAAI
Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil
2021-06-213
OAAI
Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB)
2021-05-270
PRE
Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study
2021-05-270
OA
Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
2021-01-1415
OAAI
Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America
2020-11-2810
OAAI